Device Makers Want More Protections For Collecting Off-Label Data
This article was originally published in The Gray Sheet
Executive Summary
Government agencies should create a safe harbor where industry can collect post-market clinical data without fear of being perceived as promoting off-label use, industry speakers said at the Transcatheter Cardiovascular Therapeutics conference in San Francisco last month
You may also be interested in...
FDA Issues Guidance On Off-Label Info; Waxman Seeks ‘Re-examination’
Rep. Henry Waxman is calling for the Obama administration to re-examine a final FDA guidance that gives companies a way to distribute journal articles discussing off-label uses for approved medical devices and drugs
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.